Prolactin does not delay early tumour formation of breast cancer cells, but in combination with DNA damage can trigger an anti-tumour immune response

Ödül Karayazi Atici,Carrie S. Shemanko
DOI: https://doi.org/10.1101/2020.08.31.274357
2020-09-02
Abstract:ABSTRACT There are conflicting reports of the role of prolactin in breast cancer, and its role within the context of the tumour microenvironment is not well understood. In our previous study, we demonstrated a cross-talk between the ataxia telangiectasia-mutated (ATM) DNA damage response pathway and the PRL-Janus-kinase-2 (JAK2)-signal transducer and activator of transcription-5 (STAT5)-heat shock protein-90 (HSP90) pathway. In order to investigate the role of PRL in tumour initiation and the effect of DNA damage in vivo , we used a model of breast cancer initiation that assesses the ability of breast cancer cells to initiate orthotopic xenograft tumour formation after DNA damage. Breast cancer cells engineered to secrete human PRL or the control cells, were treated with the DNA damaging agent doxorubicin or vehicle and injected into mammary fat pad of immune deficient SCID mice. PRL secretion from human breast cancer cells did not change the tumour latency compared to controls, although combined doxorubicin and PRL treatment increased tumour latency. Injection of a natural killer (NK) cell-depleting antibody, anti-asialo GM1, resulted in faster tumour formation only in the PRL-secreting breast cancer cells that were pre-treated with doxorubicin, and not PRL-only or empty vector controls. These results may shed light on the conflicting reports of PRL in breast cancer, and demonstrate that at least within the context of breast cancer cell DNA damage, that PRL exposure in the tumour microenvironment does not delay tumour initiation, but PRL together with DNA damage of breast cancer cells results in reduced tumour volume over time due to asialo-GM1-positive immune cells.
What problem does this paper attempt to address?